# Virpax Pharmaceuticals Inc. (VRPX)

Source: https://www.quantisnow.com/company/VRPX
Generated: 2026-11-10T10:46:47.670Z

- Ticker: VRPX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: virpaxpharma.com

## About

Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

## Latest VRPX news and filings

- 2025-07-21 18:57 UTC [SEC Form 25-NSE filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-virpax-pharmaceuticals-inc-6126625)
- 2025-04-03 21:00 UTC [SEC Form 8-K] [Amendment: Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-virpax-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-5976284)
- 2025-04-03 15:00 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-5974820)
- 2025-03-25 10:10 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-virpax-pharmaceuticals-inc-5958464)
- 2025-03-21 21:20 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-5956397)
- 2025-03-19 12:00 UTC [Virpax Pharmaceuticals Announces Reverse Stock Split](https://www.quantisnow.com/insight/virpax-pharmaceuticals-announces-reverse-stock-split-5951570)
- 2025-03-18 20:01 UTC [Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND](https://www.quantisnow.com/insight/virpax-receives-positive-probudur-results-for-dose-range-study-moves-5949400)
- 2025-03-17 20:31 UTC [SEC Form S-1] [SEC Form S-1 filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-virpax-pharmaceuticals-inc-5947589)
- 2025-03-07 13:00 UTC [Virpax Looking to Use MET to Develop Intranasal COVID Vaccine](https://www.quantisnow.com/insight/virpax-looking-to-use-met-to-develop-intranasal-covid-vaccine-5932530)
- 2025-03-05 21:01 UTC [Virpax's NES100 to be Presented at The Society of Toxicology by NCATS](https://www.quantisnow.com/insight/virpaxs-nes100-to-be-presented-at-the-society-of-toxicology-5927826)
- 2025-03-03 21:06 UTC [SEC Form 10-K] [SEC Form 10-K filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-virpax-pharmaceuticals-inc-5920101)
- 2025-02-27 21:01 UTC [Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology](https://www.quantisnow.com/insight/virpax-reports-positive-results-in-human-study-for-its-molecular-5914206)
- 2025-02-13 21:01 UTC [Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study](https://www.quantisnow.com/insight/virpax-confirms-positive-results-with-us-army-with-probudur-for-5887291)
- 2025-02-06 21:30 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-5875934)
- 2025-02-04 21:30 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-5870374)
- 2025-01-31 13:30 UTC [Conference Announcement] [Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference](https://www.quantisnow.com/insight/virpaxs-matthew-barnes-to-present-at-outsourcing-in-clinical-trials-5864639)
- 2025-01-30 21:04 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5863342)
- 2025-01-30 20:59 UTC [Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering](https://www.quantisnow.com/insight/spartan-capital-securities-serves-as-sole-placement-agent-in-virpax-5863263)
- 2025-01-30 14:23 UTC [Public Offering] [Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-announces-closing-of-60-million-public-offering-5862987)
- 2025-01-28 22:00 UTC [SEC Form 424B4 filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-virpax-pharmaceuticals-inc-5860286)
- 2025-01-28 14:15 UTC [Public Offering] [Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-announces-pricing-of-6-million-public-offering-5859366)
- 2025-01-28 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-virpax-pharmaceuticals-inc-5858869)
- 2025-01-17 21:32 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-virpax-pharmaceuticals-inc-5850127)
- 2025-01-15 21:31 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-virpax-pharmaceuticals-inc-5847192)
- 2025-01-15 21:05 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-5846958)
- 2025-01-08 21:11 UTC [SEC Form 3] [SEC Form 3 filed by new insider Panis Jaydriane](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-panis-jaydriane-5839671)
- 2025-01-07 21:30 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-5837808)
- 2025-01-06 21:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Chaudhry Usama](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-chaudhry-usama-5834743)
- 2024-12-30 21:47 UTC [SEC Form S-1] [SEC Form S-1 filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-virpax-pharmaceuticals-inc-5827104)
- 2024-12-30 21:05 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-5826889)
- 2024-12-18 22:00 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-5819137)
- 2024-12-13 22:15 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-5813466)
- 2024-12-09 22:29 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-virpax-pharmaceuticals-inc-5806066)
- 2024-12-05 01:30 UTC [SEC Form 3] [SEC Form 3 filed by new insider Randhawa Esha](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-randhawa-esha-5801039)
- 2024-11-29 11:39 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-5794280)
- 2024-11-26 22:01 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-5792362)
- 2024-11-22 21:31 UTC [SEC Form 8-K] [Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/virpax-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-5788642)
- 2024-11-22 13:30 UTC [Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™](https://www.quantisnow.com/insight/virpax-announces-positive-results-for-the-swine-model-dose-range-5787880)
- 2024-11-21 21:05 UTC [Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative](https://www.quantisnow.com/insight/virpax-announces-agreement-with-the-us-department-of-health-and-5786683)
- 2024-11-20 21:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Virpax Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-virpax-pharmaceuticals-inc-5784870)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VRPX
- Earnings history: https://www.quantisnow.com/earnings/VRPX
- Dividend history: https://www.quantisnow.com/dividends/VRPX
- Insider transactions: https://www.quantisnow.com/insiders/VRPX
- Options chain: https://www.quantisnow.com/options/VRPX
- SEC 8-K filings only: https://www.quantisnow.com/company/VRPX/8-k
- RSS and alerts for VRPX: https://www.quantisnow.com/docs/rss-feeds.md